Friday, July 10, 2026

pharma · Ulcerative Colitis · Multiple Myeloma

AbbVie Deutschland GmbH

APONTIS PHARMA Deutschland is a pharma organization headquartered in Wiesbaden, DE. Primary therapeutic focus areas include Ulcerative Colitis, Multiple Myeloma, Neovascular age-related macular degeneration, Psoriatic Ar

Wiesbaden, DE HQ
2018 Founded
101 Employees
EMA registrant Type
Company details
Status
Public
HQ
Wiesbaden, DE
Founded
2018
Employees
101
Programs
102
Drugs
119
Patents
23
Clinical program

ABBV-066, DEUCRAVACITINIB

Approved · small molecule · Plaque Psoriasis

ABBV-066, DEUCRAVACITINIB for Plaque Psoriasis is a Approved program (small_molecule) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).

Internal code M24-541

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
AbbVie Deutschland GmbH & Co. KG
Phase
Approved
Modality
small_molecule
Indication
Plaque Psoriasis
Status
active
Trials
1